IMC Insider Trading

Insider Ownership Percentage: 18.05%
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$31,400.00

Immuron Insider Trading History Chart

This chart shows the insider buying and selling history at Immuron by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Immuron Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for IMC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Immuron Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/12/2024Daniel PollockInsiderExercise200,000A$0.12A$24,000.00
3/8/2024Daniel PollockInsiderSell200,000A$0.16A$31,400.00
11/24/2023Paul BrennanInsiderIssued1,000,000A$0.08A$76,000.00
6/13/2022Stephen AnastasiouInsiderExpiry1,308,280A$0.10A$130,828.00
See Full Table

SEC Filings (Institutional Ownership Changes) for Immuron (ASX:IMC)

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) to reduce the risk of contracting travelers' diarrhea in the United States, and Travelers' Diarrhea; and IMM-529, for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Read More on Immuron

Today's Range

Now: N/A

50 Day Range


52 Week Range

Now: N/A


175,856 shs

Average Volume


Market Capitalization


P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Immuron?

Immuron's top insider investors include:
  1. Daniel Pollock (Insider)
  2. Paul Brennan (Insider)
  3. Stephen Anastasiou (Insider)
Learn More about top insider investors at Immuron.